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T helper cell priming of mice to Borrelia 
burgdorferi OspA leads to induction of protective 
antibodies following experimental but not tick-
borne infection 
Antibodies to the outer surface lipoprotein A (OspA) of Borrelia burgdorferi 
confer protection to SCID mice against subsequent tick-borne or experimental 
infection. However, OspA-specific antibodies are hardly detectable in naturally 
infected humans, dogs, hamsters and mice. This is most probably due to limited 
expression of OspA on spirochetes transmitted from the vector to the host. Here 
we have tested whether T cell priming of mice would lead to the induction of 
protective OspA-specific antibodies upon infection. It is shown that AKR/N 
mice, previously immunized with either a single T helper cell peptide of OspA, 
or a mixture of 27 peptides spanning the entire molecule, develop OspA-specific 
IgM or IgG antibodies, including those to a prominent protective B cell epitope 
of OspA, LA-2, within 7 days of infection with low doses (103 ) of culture-
derived spirochetes. In marked contrast, the same groups of pre-sensitized mice 
failed to generate any detectable OspA-specific antibodies after tick-borne 
infection for more than 40 days after infection. All mice, irrespective of their 
state of T cell immunity to OspA or the mode of infection, produced similar 
levels of OspC-specific IgM and IgG antibodies as early as day 14 after infection. 
None of the mice previously immunized with OspA peptides were protected 
against experimental infection, in spite of the appearance of protective anti-
bodies. It is clear from these data that, in contrast to culture-derived spiroche-
tes, the naturally transmitted pathogen fails to express OspA within the mamma-
lian host at levels sufficient for induction of B cell responses, even in the pres-
ence of pre-activated T helper cells. Together with the fact that OspA-specific 
antibodies are mainly operative by eliminating spirochetes from the vector dur-
ing infestation, the data suggest that OspA-vaccination for T helper cell immun-
ity alone is not sufficient to prevent Lyme disease. 
the infecting tick, thereby blocking bacterial transmission 
from the vector to the host [12, 13]. 
It is now well established that active and passive vaccina-
tion using OspA as immunogen leads to full protection of 
mice against subsequent tick-borne or experimental infec-
tion with Borrelia burgdorferi [l, 2]. Immunization of mice 
with either recombinant OspA lipoprotein (rLip-OspA) or 
plasmid DNA encoding OspA elicits both specific B and 
T cell responses as well as sustained levels of protective 
antibodies [2-7], in particular those related to a prominent 
protective epitope, LA-2 [8, 9]. However, full protection 
against natural or experimental infection of mice is only 
achieved when these antibodies are present before or at 
the time of challenge [1, 10, 11]. This OspA-specific 
immunity is mainly operative by killing spirochetes within 
After natural infection of humans and mice, early IgM and 
IgG antibody responses to B. burgdorferi are mainly di-
rected to flagellin ( 41 kDa) and various other antigens 
with molecular masses between 88-95 kDa, 35-39 kDa 
and 15-25 kDa, including OspC, but not to OspA [14-19]. 
Whether the absence of humoral immunity to OspA is due 
to down-regulation of this lipoprotein on spirochetes upon 
transmission by ticks [13, 20, 21] or to a permanent loss of 
OspA expression within the vertebrate host, is not clear at 
present. 
We and others have recently found that priming of mice 
with a synthetic T helper (Th) peptide of OspA leads to 
enhanced production of protective OspA-reactive anti-
bodies upon boosting with rLip-OspA [4] and to specific 
seroconversion upon challenge with low doses of cultured 
B. burgdorferi [7]. This led us to investigate whetherT cell 
priming of mice with OspA-related synthetic peptides also 
results in the induction of protective anti-OspA antibodies 
after tick-borne challenge and prevention from infection. 
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Adult female AKR/N mice were kept under specific patho-
gen free conditions at the Max-Planck-Institut filr Immun-
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biologie, Freiburg, Germany. Animals between 6 and 8 
weeks of age were used throughout the experiments. 
2.2 Spirochetes and production of recombinant antigens 
The virulent low-passage tick isolate B. burgdorferi ZS7 
was grown in Barbour-Stoenner-Kelly medium at 32 °C for 
48-72 h and harvested as described [22]. A full-length 
recombinant Lip-OspA (rLip-OspA; calculated M, 
34 kDa) from strain ZS7 was kindly provided by Smith 
Kline Beecham, Rixensart, Belgium. Briefly, the ospA 
gene encoding the Iipidated OspA was expressed in Esche-
richia coli. The soluble recombinant products were subse-
quently purified to homogeneity by gel filtration (HR-
4009), butanol extraction and Q-Sepharose chromatogra-
phy [23]. 
For expression and purification of OspC-glutathione S-
transferase fusion protein, the leader sequence, i.e. 19 N-
terminal amino acid (aa) residues, of OspC from B. burg-
dorferi ZS7 was deleted. The product was cloned into the 
BamHI/EcoRI sites of the expression vector pGEX-2T 
(Pharmacia-LKB, Freiburg, Germany). The rOspC-GST 
fusion protein was synthesized in £. coli DH5a and the 
antigen was purified as described [24]. 
2.3 Synthetic peptides 
20-mer peptides from OspA of strain ZS7 were prepared 
by solid-phase synthesis using Fmoc amino acids and DIC/ 
HOBt activation on a multiple peptide synthesizer (SMPS 
350, Zinsser Analytic Frankfurt, Germany) as described 
[25]. Peptide B4 (aa 186-203) has the following aa 
sequence: TLSKNISKSGEVSVELNDTV. The numbers 
indicate the aa positions starting from the N terminus of 
the OspA protein. 
2.4 T cell priming in vivo and challenge of mice with 
either culture-derived spirochetes or experimentally 
infected ticks 
AKR/N mice were inoculated s.c. into the base of the tail 
with 20 µg of peptide B4 emulsified in 100 µI ABM2 adju-
vant (Sebak, Aldenbach, Germany) or 54 µg of a mixture 
of 27 OspA peptides spanning the entire aa sequence of 
the OspA molecule (2 µg per peptide) in the same volume 
of ABM2 adjuvant. Control mice received ABM2 alone, 
or remained untreated. Ten days after T cell priming mice 
were challenged either s.c. with 1 x 103 viable B. burgdor-
feri (ZS7) or lxodes ricinus nymphs infected with the same 
spirochete strain as follows: Swiss mice were infected i.p. 
with 1 x 103 viable B. burgdorferi (ZS7). Two months 
later, uninfected I. ricinus larvae (50 per mouse) were 
attached onto the back of mice (protected within glued 
plastic bags). During infestation, all mice were kept in 
individual cages, placed above trays of water to recover 
ticks. After molting, nymphs were monitored for infection 
(50% of the ticks became infected with B. burgdorferi), 
and were then used to infect AKR/N mice (10 nymphs pro 
mouse) as described above. 
T cell priming to B. burgdorferi 
2.5 Analysis of immune sera for antibodies against 
OspA, OspC and against the protective B cell 
epitope, LA-2 
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Serum samples were collected at indicated time intervals 
from the tails of the mice. OspA- and OspC-specific IgG 
antibodies were measured by a solid-phase ELISA as 
described [8] with the modification that plates were coated 
with 1 µg/ml of rLip-OspA and rOspC, respectively. 
For determination of OspA-specific IgM antibodies, 96-
well microtiter plates (Nunc Immunoplate, Maxisorp, 
Roskilde, Denmark) were coated with 1 µg/ml of rLip-
OspA overnight at 4 °C. After washing with 0.05 % Tween-
20 in PBS (PBS-Tween), the plates were blocked with 
0.2 % gelatine in PBS for 2 h at room temperature with 
shaking. Subsequently, the plates were incubated for 2 h 
with 100 µI of serially twofold diluted immune sera and 
seven control sera from naive AKR/N mice (beginning at 
1: 50 in PBS-Tween). After incubation with alkaline 
phosphatase-conjugated goat anti-mouse lgM (1: 1000 in 
PBS-Tween, Southern Biotechnology Association, Inc., 
Birmingham, AL) for 90 min, the substrate p-nitrophenyl 
phosphate (Sigma 104 phosphatase substrate tablets, 
St. Louis, MO) was added for 15 min in the dark. Finally, 
the absorbance was read at 490 nm using an ELISA 
reader. To determine the end-point titer of test sera, the 
mean and standard deviation (SD) of the seven negative 
control sera were determined. The final titer of an immune 
serum is defined as the dilution showing absorbance values 
~ mean plus 2 SD of control sera. Serum LA-2 equivalent 
antibodies were determined by a mAb LA-2 competition 
ELISA as described [5]. 
2.6 Passive immunization and recultivation of spirochetes 
from biopsies 
The 6-8-week-old female C.B.-17 SCID mice (H-2d) were 
injected i.p. with either serial dilutions of pooled AKR/N 
immune sera (100 µI/mouse), mAb LA-2 (5 µg/mouse), or 
PBS. After 2 h, each recipient was injected s.c. with 
1 x 103 B. burgdorferi ZS7 into the base of the tail. C.B.-
17 SCID mice were monitored for the development of clin-
ical arthritis in the tibiotarsal joints as described [22] and 
for the presence of spirochetes by cultivation of ear biop-
sies, taken between days 12 and 96 [5, 26]. 
3 Results and discussion 
It was shown recently that Th cell priming of mice with 
synthetic peptides of OspA leads to an early and enhanced 
appearance of OspA-specific antibodies, including those 
with protective potential [4], when challenged with either 
rLip-OspA or low doses (::::; 103) of culture-derived spiro-
chetes [4, 7]. In the present study, we tested whether the 
same protocol of Th cell priming would also favor induc-
tion of OspA-reactive and protective antibodies after tick-
borne infection of mice. 
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Table 1. Amount of OspA-specific lgG antibodies and protective LA-2 equivalents (µg/ml) in sera of AKR/N mice after priming with 
OspA peptide B4 (aa 186-203) and subsequent challenge with culture-derived B. burgdorferi zs7•> 
Day -3 Day 20 after infection Day 45 after infection 
Priming Anti-OspA IgG Anti-OspA lgG LA-2 Eq Anti-OspA lgG LA-2 Eq 
ABM2 <0.1 3.1±1.1 0.9 ± 0.4 4.3 ± 3.8 2.3 ± 0.8 
(n = 6) 
B4 +ABM2 <0.1 12.5 ± 7.3 4.4 ± 1.6 17.7 ± 8.9 9.6 ± 5.7 
(n = 8) 
p valueb> C) 0.0007 0.0007 0.0027 0.007 
a) AKR/N mice were primed with 20 µg of OspA peptide B4 s.c. 10 days before challenge. The day of the challenge with spirochetes 
is defined as day 0. Control sera were taken 7 days after priming with peptide (day -3). After challenge with 1 x 103 B. burgdorferi 
ZS7 s.c. in the base of the tail, the concentration of OspA-specific lgG antibodies as well as the protective LA-2 equivalent IgG anti-
bodies (LA-2 Eq) from individual mouse sera were determined by a quantitative ELISA and a mAb LA-2 competition ELISA at 
days 20 and 45. The data are expressed as the mean ± SD. 
b) p values were obtained by the nonparametric Mann-Whitney test by comparison of B4-primed groups with ABM2 adjuvant-primed 
control groups. A p value smaller than 0.05 is considered significant. 
c) Calculation not possible. 
AKR/N mice were immunized with either one of the 
prominent Th cell-specific peptides of OspA, i.e. B4 [4], or 
a mixture of 27 peptides spanning the entire OspA mole-
cule in adjuvant (ABM2), or with ABM2 alone. Untreated 
mice served as an additional control. Priming of the T cell 
compartment by peptide preparations was confirmed by 
showing that enriched CD4" T cell populations from mice 
presensitized with peptide B4 (aa 186-203) could be spe-
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Figure 1. Kinetics of appearance of anti-OspA (A, B, E, F) and anti-OspC (C, D, G, H) antibodies in serum of AKR/N mice previously 
primed with OspA-related peptide preparations and subsequently challenged with either 103 cultured B. burgdorferi ZS7 (upper panel) 
or infected ticks (lower panel). Pretreatment of AKR/N mice: (1) none (squares); (2) ABM2 (100 µl; diamonds); (3) peptide B4 (20 µg 
in 100 µl of ABM2; circles); or (4) overlapping OspA-related peptide mixture covering the entire OspA molecule (54 µgin 100 µl of 
ABM2; triangles). Ten days later animals were injected with 1 x 103 B. burgdorferi ZS7 s.c. into the base of the tail or naturally infected 
via /. ricinus nymphs infected with B. burgdorferi ZS7. lgG antibodies against OspA and OspC were determined from pooled sera 
(upper panel: 3 mice/group; lower panel: 5 mice/group) by a quantitative ELISA as described in Sect. 2.5. IgM antibodies to OspA and 
OspC were measured from the same pooled sera by a semi-quantitative ELISA. Results are end-point titers of serum dilutions whose 
absorbance values arc greater than the mean -t 2 SD of seven normal sera from naive AKR/N mice. 
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Table 2. Development of clinical arthritis and persistence of spirochetes in AKR/N mice previously primed with OspA-peptide pre-
parations and subsequently challenged with B. burgdorferi ZS7"l 
Priming Clinical arthritisbl Re-cultivation of spi-
rochetescJ 
Experiment 1 
Experiment 2 
Untreated 
ABM2 
B4 + ABM2 
Peptide mix. + ABM2 
ABM2 
B4 +ABM2 
3/3 
3/3 
3/3 
3/3 
4/6 
717 
3/3 
3/3 
3/3 
2/3 
616 
8/8 
a) Data of experiment 1 and 2 were obtained after syringe inoculation from the mice groups described in Fig. 1 and Table 1, respec-
tively. 
b) Development of clinical arthritis was monitored for 58 days (Experiment 1) and 98 days after infection (Experiment 2), respectively 
(number of mice with clinical tibiotarsal arthritis/number of mice examined). 
c) Recultivation of spirochetes from ear biopsies 32 days (Experiment 1) and 45 days after infection (Experiment 2), respectively ( num-
ber of positive cultures/number of mice tested). 
Table 1, at days 20 and 45, the amount of anti-OspA serum 
lgG antibodies detected was approximately fourfold 
higher in mice presensitized with B4 + ABM2 as com-
pared to ABM2 alone. No specific antibodies were 
observed in B4-primed but unchallenged mice (day -3). 
In the next step, the kinetics of IgM and IgG antibody 
responses to OspA were monitored in more detail for up to 
42 days after infection in pooled sera from peptide-primed 
and control AKR/N mice, subsequently challenged with 
either 103 culture-derived spirochetes or with infected /. 
ricinus nymphs. AKR/N mice, previously immunized with 
either B4 or ABM2 alone, but not untreated control mice, 
produced similar amounts of OspA-specific lgM anti-
bodies (IgM: di!. 1/400) upon experimental challenge 
(Fig. lA). The lack of specificity may be due to an unspe-
cific activation of the IgM response by ABM2. However, 
upon immunization of mice with a mixture of 27 OspA 
peptides spanning the entire OspA molecule and including 
various T cell-reactive epitopes [4], the level of OspA-
specific IgM antibodies observed at days 7 and 14 after 
infection. (lgM: di!. 1/800) significantly exceeded those 
obtained with B4 + ABM2 or ABM2 alone. From day 14 
to day 30 after infection, the amount of OspA-reactive 
IgM antibodies rapidly declined to baseline levels. When 
tested for OspA-specific lgG antibodies, significantly 
higher amounts were found in B4-sensitized as compared 
to ABM2-treated mice. The respective antibodies were 
already detectable 7 days after infection. (IgG: 1.7 µg/ml); 
their level further increased with time, reaching a plateau 
of - 7 µg/ml at day 30 (Fig. lB). No OspA-specific anti-
bodies were found in B4-primed but unchallenged mice up 
to 35 days after initial priming (data not shown), demon-
strating that peptide B4 alone was unable to induce B cell 
responses. Immunization of mice with the mixture of 
OspA peptides resulted in even higher levels of OspA-
specific IgG antibodies at day 14 after infection (14.3 µg/ 
ml) which declined with time (Fig. lB). The remote possi-
bility that the increased amounts of OspA-specific anti-
bodies produced by this protocol is, at least, partially due 
to previous B cell activation by putative B cell epitopes 
present in the peptide mixture of OspA could not be 
excluded. However, the latter protocol did not change the 
kinetics of appearance of OspA-specific antibodies as 
observed with B4. In marked contrast, none of the naive 
or presensitized mice produced detectable amounts of 
OspA-specific antibodies following tick challenge during 
the entire observation period (Fig. lE and F). As expected 
from previous studies [17, 27], mice of all experimental 
groups produced significant amounts of OspC-specific IgM 
and IgG antibodies in response to both, tick-borne 
(Fig. 1 G, H) and culture-derived spirochetes 
(Fig. lC, D), as early as 14 days after infection. The level 
of anti-OspC antibodies was not affected by previous sen-
sitization with OspA peptides. Again, the unspecific acti-
vation of the immune system by ABM2 is indicated by the 
fact that levels of lgM and/or lgG antibodies to OspC were 
mostly higher in adjuvant-treated as compared to control 
mice (Fig. lG, H). 
Together, the data allow to draw the following conclusions. 
First, when spirochetes are inoculated at low doses ( ~ 
103), the amount of immunogenic OspA available seems to 
be limited. An effective induction of anti-OspA antibodies 
is only achieved in the presence of presensitized T helper 
cells. This finding confirms and extends previous studies 
showing that culture-derived spirochetes only transiently 
express OspA in vivo [20] and switch to OspC expression, 
explaining why experimentally infected mice only serocon-
verted to OspC, but not to OspA ([17, 18, 21, 27] and data 
shown here). Obviously, the amount of OspA antigen 
expressed by the pathogen within mice is too low to induce 
an antibody response on its own, but is sufficient to do so 
in the presence ofT cell help. Second, tick-transmitted spi-
rochetes are devoid of OspA. Moreover, they do not seem 
to re-express the antigen in the mammalian host. This 
assumption is supported by recent studies describing 
differential expression patterns for OspA on spirochetes in 
ticks and mice, as determined by mRNA analysis and indi-
rect immunofluorescence: whereas spirochetes express 
OspA in unfed ticks [20, 28] they rapidly down-regulate 
this molecule during the course of tick infestation and their 
concomitant transmission into mice [13, 20]. Furthermore, 
the biological read-out system of Th cell-supported anti-
body production used in this study strongly suggests that 
OspA is absent from spirochetes during the observed pe-
riod of infection (day 42 after infection) and does not serve 
as an appropriate target structure for protective antibodies 
within the mammalien host. 
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It is well established that B. burgdorferi persists in wild 
rodents and experimental animals in the presence of high 
concentrations of spirochete-specific antibodies [19, 
29-31). Subsequent studies in mice showed that protective 
antibodies must be present before or early during infection 
to readily eradicate spirochetes from hosts [1, 10, 11] and 
that therapeutic vaccination with OspA does not resolve 
B. burgdorferi infection in mice [32). Consequently, we 
monitored the effect of T cell priming on the development 
of clinical arthritis and clearance of spirochetes upon 
syringe challenge. The course of clinical arthritis observed 
in AKR/N mice previously primed with either B4 or the 
peptide mix was similar to that of control animals, both 
with respect to the kinetics of the appearance and severity 
(Table 2, and data not shown). In addition, with one 
exception (Experiment 1; peptide mix), spirochetes could 
be recovered from all recipients on day 42 after infection, 
independent of their pretreatment. Thus, although Th cell 
priming of mice leads to the induction of OspA-specific 
antibodies upon experimental challenge [7), the humoral 
response generated was still inadequate to efficiently con-
trol the disease and/or to eliminate spirochetes. 
To test whether this was due to the lack of protective anti-
bodies, we determined the amount of LA-2-related anti-
bodies in immune sera of individual B4-primed AKR/N 
mice upon syringe inoculation. Antibodies to the B cell 
epitope of OspA, defined by the mAb LA-2, have been 
shown before to be positively correlated with protection 
[8, 9, 33). As seen in Table 1, the amount of LA-2-related 
antibodies was approximately four times higher in pooled 
sera from mice pretreated with B4 ( + ABM2) than in mice 
pretreated with ABM2 alone when tested at days 20 and 45 
following experimental challenge. The protective potential 
of immune sera from B4-primed and ABM2-treated con-
trol mice was further evaluated in passive transfer experi-
ments. We found that complete frotection of SCID mice 
against syringe challenge with 10 B. burgdorferi ZS7 was 
still achieved with 11320 diluted immune sera from mice 
pretreated with B4 + ABM2 but that a dilution of 11160 
was required in case of diluted sera from mice pretreated 
with ABM2 (data not shown). Thus, Th cell priming of 
mice to OspA and subsequent experimental challenge 
leads to induction of OspA-specific antibodies at amounts 
sufficient to convey protection upon passive transfer into 
SCID mice. However, for an effective control of an ongo-
ing experimental infection, the critical level of these anti-
bodies seems to accumulate too late. 
In conclusion, the results demonstrate that T cell priming 
to OspA does not lead to induction of OspA-specific anti-
bodies upon tick-borne infection and protection against 
disease. In addition, the data suggest that vector-derived 
spirochetes are devoid of OspA and do not re-express this 
antigen in the mammalian environment, at least during 
early stages of infection. Together with previous findings 
that OspA-specific antibodies are only protective when 
available before or shortly after infection [1, 10, 11] and 
that they mainly act by eliminating spirochetes within the 
tick gut [2, 13), the presented data emphasize that OspA-
based prevention of Lyme disease is only achieved by vac-
cination protocols leading to a state of sustained OspA-
specific humoral immunity. 
Eur. J. Immunol. 1997. 27: 2942-2947 
We would like to thank Christiane Brenner, Gudrun Prehn, Olivier 
Rais, and Thomas Stehle for expert technical assistance and 
Annette Siebers and Stefan Kanzok for critically reading the 
manuscript. This study was supported in part by the Bundesmini-
sterium fiir Forschung und Technologie, Germany (OJ Kl 9506) 
and by SmithKline Beecham. 
4 References 
1 Schaible, U. E., Kramer, M. D., Eichmann, K., Modolell, M., 
Museteanu, C. and Simon, M. M., Proc. Natl. Acad. Sci. USA 
1990. 87: 3768. 
2 Fikrig, E., Barthold, S. W., Kantor, F. S. and Favell, R. A., 
Science 1990. 250: 553. 
3 Schaible, U. E., Wallich, R., Kramer, M. D., Nerz, G., Stehle, 
T., Museteanu, C. and Simon, M. M., lnt. lmmunol. 1994. 6: 
671. 
4 Zhong, W. M., Wiesmtiller, K. H., Kramer, M. D., Wallich, R. 
and Simon, M. M., Eur. J. lmmunol. 1996. 26: 2749. 
5 Simon, M. M., Gern, L., Hauser, P., Zhong, W. M., Nielsen, 
P. J., Kramer, M. D., Brenner, C. and Wallich, R., Eur. J. 
lmmunol. 1996. 26: 2831. 
6 Luke, C. J., Carner, K., Liang, X. W. and Barbour, A.G., J. 
Infect. Dis. 1997. 175: 91. 
7 Bockenstedt, L. K., Fikrig, E., Barthold, S. W., Flavell, R. A. 
and Kantor, F. S., J. lmmunol. 1996. 157: 5496. 
8 Kramer, M. D., Schaible, U. E., Wallich, R., Moter, S., Pet-
zoldt, D. and Simon, M. M., lmmunobiology 1990. 181: 357. 
9 Johnson, B., Sviat, S. L., Happ, C. M., Dunn, J. J., Frantz, J. 
C., Mayer, L. W. and Piesman, J., Vaccine 1995. 13: 1086. 
10 Schaible, U. E., Wallich, R., Kramer, M. D., Gern, L., Ander-
son, J. F., Museteanu, C. and Simon, M. M., Vaccine 1993. 11: 
1049. 
11 Barthold, S. W., deSouza, M. and Feng, S., Lab. Invest. 1996. 
74: 67. 
12 Fikrig, E., Telford, S. R. III, Barthold, S. W., Kantor, F. S., 
Spielman, A. and Flavell, R. A., Proc. Natl. Acad. Sci. USA 
1992. 89: 5418. 
13 De Silva, A. M., Telford, S. R. III, Brunet, L. R., Barthold, 
S. W. and Fikrig, E., J. Exp. Med. 1996. 183: 271. 
14 Wilske, B., Preac-Mursic, V., Schierz, G. and Busch, K. V., 
Zentralbl. Bakteriol. Hyg. A. 1986. 263: 92. 
15 Craft, J.E., Fischer, D. K., Shimamoto, G. and Steere, A. C., 
J. Clin. Invest. 1986. 78: 934. 
16 Dressler, F., Whalen, J. A., Reinhardt, B. N. and Steere, A. 
C., J. Infect. Dis. 1993. 167: 392. 
17 Schaible, U. E., Gern, L., Wallich, R., Kramer, M. D., Pre-
ster, M. and Simon, M. M., Immunol. Lett. 1993. 36: 219. 
18 Gern, L., Schaible, U. E. and Simon, M. M., J. Infect. Dis. 
1993. 167: 971. 
19 Barthold, S. W., J. Spirochetal Tick-borne Dis. 1996. 3: 22. 
20 Schwan, T. G., Piesman, J., Gilde, W. T., Dolan, M. C. and 
Rosa, P.A., Proc. Natl. Acad. Sci. USA 1995. 92: 2909. 
21 Montgomery, R. R., Malawista, S. E., Feen, K. J. M. and 
Bockenstedt, L. K., J. Exp. Med. 1996. 183: 261. 
22 Schaible, U. E., Gay, S., Museteanu, C., Kramer, M. D., Zim-
mer, G., Eichmann, K., Museteanu, U. and Simon, M. M., 
Am. J. Pathol. 1990. 137: 811. 
23 Gem, L., Rais, 0., Capiau, C., Hauser, P., Lobet, Y., Simoen, 
E., Voet, P. and Petre, J., lmmunol. Lett. 1994. 39: 249. 
24 Wallich, R., Brenner, C., Kramer, M. D. and Simon, M. M., 
Infect. lmmun. 1995. 63: 3327. 
25 Wiesmtiller, K. H., Handtman, D., Schneider, F., Jung, G. 
and Muller, C. P., J. Gen. Viral. 1992. 73: 2211. 
26 Sinsky, R. J. and Picsman, J., J. Clin. Microbial. 1989. 27: 
1723. 
27 Golde, W. T., Kappel, K. J., Dequesne, G., Feron, C., Plain-
champ, D., Capiau, C. and Lobet, Y., Infect. lmmun. 1994. 
62: 2625. 
28 Fingerle, V., Hauser, U., Liegl, G., Petko, B., Preac-Mursic, 
V. and Wilske, B., J. Clin. Microbial. 1995. 33: 1867. 
5
Eur. J. lmmunol. 1997. 27: 2942-2947 
29 Schaible, U. E., Wallich, R., Kramer, M. D., Museteanu, C., 
Rittig, M., Moter, S. and Simon, M. M., in Schutzer, S. E. 
(Ed.), Current Communication in cell and Molecular Biology, 
Cold Spring Harbor Laboratory Press, Cold Spring Harbor 
1992, p. 243. 
30 Magnarelli, L. A. and Anderson, J. F., J. Clin. Microbial. 
1988. 26: 1482. 
T cell priming to B. burgdorferi 2947 
31 Schwan, T. G., Kime, K. K., Schrumpf, M. E., Coe, J.E. and 
Simpson, W. J., Infect. Immun. 1989. 57: 3445. 
32 Fikrig, E., Barthold, S. W. and Flavell, R. A., Infect. Immun. 
1993. 61: 2553. 
33 Golde, W. T., Piesman, J., Dolan, M. C., Kramer, M., Hauser, 
P., Lobet, Y., Capiau, C., Desmons, P., Voet, P., Dearwestcr, 
D. and Frantz, J.C., Infect. Immun. 1997. 65: 882. 
6
